AU2670297A - Inhibitors of farnesyl-protein transferase - Google Patents

Inhibitors of farnesyl-protein transferase

Info

Publication number
AU2670297A
AU2670297A AU26702/97A AU2670297A AU2670297A AU 2670297 A AU2670297 A AU 2670297A AU 26702/97 A AU26702/97 A AU 26702/97A AU 2670297 A AU2670297 A AU 2670297A AU 2670297 A AU2670297 A AU 2670297A
Authority
AU
Australia
Prior art keywords
farnesyl
inhibitors
protein transferase
transferase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU26702/97A
Other versions
AU715658B2 (en
Inventor
Neville Anthony
Christopher Dinsmore
Robert Gomez
Gerald E. Stokker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613462.2A external-priority patent/GB9613462D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2670297A publication Critical patent/AU2670297A/en
Application granted granted Critical
Publication of AU715658B2 publication Critical patent/AU715658B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AU26702/97A 1996-04-03 1997-04-01 Inhibitors of farnesyl-protein transferase Ceased AU715658B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1459296P 1996-04-03 1996-04-03
US60/014592 1996-04-03
GBGB9613462.2A GB9613462D0 (en) 1996-06-27 1996-06-27 Inhibitors of farnesyl-protein transferase
GB9613462 1996-06-27
PCT/US1997/006257 WO1997036876A1 (en) 1996-04-03 1997-04-01 Inhibitors of farnesyl-protein transferase

Publications (2)

Publication Number Publication Date
AU2670297A true AU2670297A (en) 1997-10-22
AU715658B2 AU715658B2 (en) 2000-02-10

Family

ID=26309577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26702/97A Ceased AU715658B2 (en) 1996-04-03 1997-04-01 Inhibitors of farnesyl-protein transferase

Country Status (5)

Country Link
EP (1) EP0891334A1 (en)
JP (1) JP2000507955A (en)
AU (1) AU715658B2 (en)
CA (1) CA2249615A1 (en)
WO (1) WO1997036876A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243507A1 (en) * 1996-01-30 1997-08-07 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100375421B1 (en) * 1997-07-15 2003-05-12 주식회사 엘지생명과학 Farnesyl transferase inhibitor having anti-tumor properties
JP3548118B2 (en) 1997-11-28 2004-07-28 エルジ ケミカル リミテッド Imidazole derivatives having farnesyl transferase inhibitory activity and method for producing the same
KR100388791B1 (en) * 1998-06-23 2003-10-10 주식회사 엘지생명과학 Panesyltransferase inhibitors having a thiazole or oxazole structure and preparation method thereof
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
WO2000064891A1 (en) * 1999-04-13 2000-11-02 Lg Chem Investment Ltd. Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof
KR20010063274A (en) * 1999-12-22 2001-07-09 성재갑 Pharmaceutical composition containing [1-{[1-(1,3-benzodioxol-5-ylmethyl)-1H-imidazol-5-yl] methyl}-4-(1-naphthyl)-1H-pyrrol-3-yl](4-methyl-1-piperazinyl)methanone for anticancer agent
WO2001076694A1 (en) 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer
MXPA02012712A (en) 2000-06-30 2003-04-25 Bristol Myers Squibb Pharma Co N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
EP1310485A4 (en) 2000-07-28 2005-07-20 Sumitomo Pharma Pyrrole derivatives
US7211595B2 (en) 2000-11-30 2007-05-01 Abbott Laboratories Farnesyltransferase inhibitors
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006109085A1 (en) 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
KR101589551B1 (en) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DK2404919T3 (en) 2005-11-08 2013-11-04 Vertex Pharma Heterocyclic compound suitable as modulator of ATP binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2009526059A (en) 2006-02-07 2009-07-16 ワイス 11-beta HSD1 inhibitor
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
MX2010006183A (en) 2007-12-07 2010-10-15 Vertex Pharma Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids.
BRPI0821039B8 (en) 2007-12-07 2021-05-25 Vertex Pharma solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, process for their preparation , pharmaceutical compositions comprising the same and uses
JP5523352B2 (en) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Heteroaryl derivatives as CFTR modifiers
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
ES2446971T3 (en) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahydroisoquinolines substituted with aryl, heteroaryl, and heterocycle and their use
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
JP2013523833A (en) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3- (6- (1- (2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical composition and Its administration
CN105848657B (en) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 Methods of making pharmaceutical compositions for treating CFTR mediated diseases
HUE055423T2 (en) 2014-11-18 2021-11-29 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234104B1 (en) 1985-12-03 1990-10-24 Sumitomo Chemical Company, Limited Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
EP0246749A3 (en) 1986-05-17 1988-08-31 AgrEvo UK Limited Triazole herbicides
JP2521077B2 (en) 1987-02-13 1996-07-31 住友化学工業株式会社 Pyridyltriazine derivative and plant disease control agent containing the same
US4837333A (en) * 1987-05-14 1989-06-06 G. D. Searle & Co. Substituted alkylidene imidazoles
DE3811574A1 (en) * 1988-03-31 1989-10-19 Schering Ag N-SUBSTITUTED IMIDAZOLES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS
DE3813885A1 (en) 1988-04-20 1989-11-02 Schering Ag 1-CHLORPYRIMIDINYL-1H-1,2,4-TRIAZOL-3-SULPHONIC ACID AMIDE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AGENT WITH HERBICIDES, FUNGICIDES AND PLANT GROWTH REGULATING EFFECT
FR2657610A1 (en) 1990-01-29 1991-08-02 Rhone Poulenc Agrochimie TRIAZOLOPYRIDINES HERBICIDES.
JP3163545B2 (en) 1991-06-24 2001-05-08 八洲化学工業株式会社 4-thienyl-oxa (thia) azoline derivatives and insecticides and acaricides containing the same
JPH05201974A (en) 1991-11-25 1993-08-10 Sumitomo Chem Co Ltd Heterocyclic compound and herbicide containing the compound as active component
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
EP0694535A1 (en) 1994-04-29 1996-01-31 Eli Lilly And Company Non-peptidyl tachykinin receptor antagonists

Also Published As

Publication number Publication date
CA2249615A1 (en) 1997-10-09
AU715658B2 (en) 2000-02-10
JP2000507955A (en) 2000-06-27
EP0891334A1 (en) 1999-01-20
WO1997036876A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
AU703203B2 (en) Inhibitors of farnesyl-protein transferase
AU2734797A (en) Inhibitors of farnesyl-protein transferase
AU2670297A (en) Inhibitors of farnesyl-protein transferase
AU2593097A (en) Inhibitors of farnesyl-protein transferase
AU2253097A (en) Inhibitors of farnesyl-protein transferase
AU2430197A (en) Inhibitors of farnesyl-protein transferase
AU1988495A (en) Inhibitors of farnesyl-protein transferase
AU2555997A (en) Inhibitors of farnesyl-protein transferase
AU3373195A (en) Inhibitors of farnesyl-protein transferase
AU2598897A (en) Inhibitors of farnesyl-protein transferase
AU2605897A (en) Inhibitors of farnesyl-protein transferase
GB9604311D0 (en) Inhibitors of farnesyl-protein transferase
AU2552497A (en) Inhibitors of farnesyl-protein transferase
AU2605797A (en) Inhibitors of farnesyl-protein transferase
AU1851697A (en) Inhibitors of farnesyl-protein transferase
AU2587597A (en) Inhibitors of farnesyl-protein transferase
AU2432697A (en) Inhibitors of farnesyl-protein transferase
AU2432597A (en) Inhibitors of farnesyl-protein transferase
AU2430397A (en) Inhibitors of farnesyl-protein transferase
AU2554897A (en) Inhibitors of farnesyl-protein transferase
EP0891352A4 (en) Inhibitors of farnesyl-protein transferase
AU2600597A (en) Inhibitors of farnesyl-protein transferase
AU2602097A (en) Inhibitors of farnesyl-protein transferase
AU2593297A (en) Inhibitors of farnesyl-protein transferase
AU1952697A (en) Inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired